v3.26.1
Segment Information - Schedule of Financial Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items]          
Revenue   $ 0 $ 70,000 $ 0 $ 70,000
Operating Expenses:          
Research and development   584,000 2,253,000 1,787,000 4,856,000
General and administrative   3,408,000 2,685,000 7,146,000 5,930,000
Operating loss   (3,992,000) (4,868,000) (8,933,000) (10,716,000)
Other income, net   1,063,000 209,000 1,128,000 371,000
Benefit from income taxes $ 387,000 0 0 (387,000) (962,000)
Net loss   (2,929,000) (4,659,000) (7,418,000) (9,383,000)
Reportable Segment          
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items]          
Revenue   0 70,000 0 70,000
Operating Expenses:          
Research and development   584,000 2,253,000 1,787,000 4,856,000
General and administrative   3,408,000 2,685,000 7,146,000 5,930,000
Investor relations/public relations/communications   214,000 309,000 451,000 640,000
Finance   598,000 538,000 1,183,000 1,167,000
Legal   760,000 327,000 1,854,000 551,000
Business development   156,000 140,000 305,000 267,000
Share based compensation expense   178,000 212,000 471,000 616,000
Other   19,000 2,000 66,000 387,000
Operating loss   (3,992,000) (4,868,000) (8,933,000) (10,716,000)
Other income, net   1,063,000 209,000 1,128,000 371,000
Benefit from income taxes   0 0 (387,000) (962,000)
Net loss   (2,929,000) (4,659,000) (7,418,000) (9,383,000)
Cash and marketable securities   10,443,000 21,970,000 10,443,000 21,970,000
Reportable Segment | Corporate          
Operating Expenses:          
General and administrative   1,483,000 1,157,000 2,816,000 2,302,000
Reportable Segment | BOLSTER trial          
Operating Expenses:          
Research and development   (270,000) 605,000 (320,000) 1,393,000
Reportable Segment | ASCEND trial          
Operating Expenses:          
Research and development   27,000 32,000 201,000 53,000
Reportable Segment | Chemistry, manufacturing and controls          
Operating Expenses:          
Research and development   199,000 167,000 390,000 387,000
Reportable Segment | Clinical department          
Operating Expenses:          
Research and development   586,000 991,000 1,354,000 2,148,000
Reportable Segment | Other          
Operating Expenses:          
Research and development   $ 42,000 $ 458,000 $ 162,000 $ 875,000